Have you or a loved one been newly diagnosed with acute myeloid leukemia (AML)? Find out if it is RARA-positive AML.

Ask your doctor about participating in the clinical trial of Syros's oral investigational treatment tamibarotene (formerly SY-1425) to find out if you are RARA-positive.

~30% of all AML patients are RARA-positive

NOW ENROLLING SELECT-AML-1 PHASE 2 TRIAL:

Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML (ClinicalTrials.gov identifier: NCT04905407)

Patients are randomized to receive either tamibarotene with venetoclax/azacitidine, which is currently the standard of the care for AML patients that are not eligible to receive chemothotherapy, or venetoclax/azacitidine without tamibarotene.



Trial summary: Tamibarotene is being studied as a treatment for participants with AML whose cancer has a specific genetic abnormality characterized by the overexpression of the retinoic acid receptor alpha (RARA) gene. This trial is designed to evaluate the safety and efficacy of tamibarotene in combination with venetoclax and azacitidine compared to venetoclax and azacitidine. The primary goal of the study is to compare the composite complete response (CR) rate between the two arms.

About RARA testing: A blood test will be used to identify participants with RARA-positive AML. Assessment of the RARA biomarker for study eligibility will be done by collection of blood samples from potential study participants at the pre-screening visit and testing at a central laboratory.

Trial participant eligibility key criteria:

- 18 years of age and older
- RARA-positive, based on the investigational assay
- Newly diagnosed with non-acute promyelocytic leukemia (APL) AML
- Unlikely to tolerate standard intensive chemotherapy
- Have not received prior treatment for AML or myelodysplastic syndromes (MDS)

SYROS

An expression makes a world of difference

Contact your doctor to discuss participation in the SELECT-AML-1 trial. For more information about the trial visit ClinicalTrials.gov and search NCT04905407.

Syros is a biopharmaceutical company redefining the power of small molecules to control the expression of genes. Based in Cambridge, Mass., Syros is developing a pipeline of clinical-stage candidates that aim to provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Tamibarotene is an investigational agent and has not been approved by the FDA as a treatment for any indication.